Baillie Gifford & Co. Trims Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Baillie Gifford & Co. cut its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,012,727 shares of the medical research company's stock after selling 196,774 shares during the period. Baillie Gifford & Co. owned 0.55% of Exact Sciences worth $56,905,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of EXAS. AMF Tjanstepension AB bought a new position in Exact Sciences in the 3rd quarter worth approximately $724,000. Creative Planning boosted its holdings in Exact Sciences by 14.8% in the 3rd quarter. Creative Planning now owns 38,060 shares of the medical research company's stock worth $2,593,000 after buying an additional 4,906 shares during the period. V Square Quantitative Management LLC bought a new position in Exact Sciences in the 3rd quarter worth approximately $47,000. Blue Trust Inc. lifted its stake in Exact Sciences by 61.0% in the 3rd quarter. Blue Trust Inc. now owns 5,220 shares of the medical research company's stock worth $356,000 after purchasing an additional 1,978 shares in the last quarter. Finally, Chicago Capital LLC purchased a new stake in Exact Sciences in the 3rd quarter worth approximately $303,000. 88.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

EXAS has been the topic of several recent analyst reports. Bank of America lowered their target price on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday. Robert W. Baird lowered their target price on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. TD Cowen increased their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Evercore ISI lowered their target price on shares of Exact Sciences from $80.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Finally, Piper Sandler lowered their target price on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and an average price target of $72.06.

Exact Sciences Stock Down 0.5 %

Exact Sciences stock traded down $0.25 during midday trading on Friday, hitting $49.26. 3,339,540 shares of the company's stock were exchanged, compared to its average volume of 2,338,169. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The firm has a 50-day moving average of $54.91 and a two-hundred day moving average of $59.99. The company has a market cap of $9.12 billion, a PE ratio of -8.84 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 4.97%. The company had revenue of $713.42 million for the quarter, compared to analysts' expectations of $701.45 million. As a group, analysts expect that Exact Sciences Co. will post -0.59 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.